TUDCA 500 mg – 60 capsules (preorder)

TUDCA 500 mg — 60 research capsules. Tauroursodeoxycholic acid is one of the most pharmacologically validated bile-acid chaperones in modern hepatology and cell biology. Approved as a hepatoprotective drug in several jurisdictions and a long-standing first-line cholagogue in traditional Chinese medicine, TUDCA combines two of the rarest properties in molecular pharmacology: an exceptionally clean human safety record dating back decades, and a documented mechanism — endoplasmic-reticulum-stress chaperoning — that places it at the centre of contemporary research on metabolic disease, neurodegeneration and mitochondrial dysfunction. The 500 mg per-capsule potency matches the dose increment most frequently reported in published clinical pharmacology, allowing finer titration across study protocols.

Research Overview

TUDCA is the taurine-conjugated form of ursodeoxycholic acid (UDCA) — the same hepatoprotective molecule used clinically for primary biliary cholangitis. Mechanistically, TUDCA acts as a chemical chaperone that stabilizes mis-folded proteins in the endoplasmic reticulum, suppresses the unfolded-protein response (PERK/IRE1α/ATF6), and inhibits mitochondrial outer-membrane permeabilization and downstream apoptotic signaling [1,2]. Because ER stress and mitochondrial apoptosis are convergent pathways in obesity, type-2 diabetes, ALS, Huntington’s, Parkinson’s, retinal degeneration and ischemia-reperfusion injury, TUDCA has become a workhorse research tool across these disparate fields [1–3]. In a randomized human study in obese non-diabetic adults, four-week oral TUDCA improved hepatic and muscle insulin sensitivity by ~30 % [3]. Its safety profile across decades of clinical use — well-tolerated even at multi-gram daily doses — is unmatched among bile-acid pharmaceuticals.

Primary Research Areas

• ER stress and unfolded-protein-response (UPR) modulation — the prototype small-molecule chaperone, used as a positive control to interrogate PERK/IRE1α/ATF6 signaling in countless cell-stress models [1,4].
• Hepatic and metabolic research — improves hepatic insulin sensitivity in human RCTs and mitigates steatosis, lipotoxicity and gluconeogenic dysregulation in NAFLD/MASH preclinical models [3,4].
• Mitochondrial cytoprotection and apoptosis — stabilizes mitochondrial membrane potential, prevents cytochrome-c release and inhibits Bax-mediated permeabilization in cardiac, hepatic and neuronal models [2].
• Neurodegeneration models — evaluated in ALS, Huntington’s, Parkinson’s, stroke and retinal-degeneration paradigms; Phase II/III data exist for ALS [1,7,8,9].
• Cholestatic and gallbladder research — the parent application area; well-characterized effects on biliary flow, cholesterol saturation and choleretic kinetics [1,5].
• Liver, head to head with the standard drug — in 199 people with primary biliary cholangitis, 24 weeks of TUDCA matched ursodeoxycholic acid, the standard treatment, on the main liver-enzyme response (76% vs 81%, no significant difference). It matters because it means TUDCA was not weaker than the standard treatment in this disease [5].
• Insulin sensitivity — in 20 adults with obesity, four weeks at 1,750 mg a day raised insulin sensitivity in liver and muscle by about 30%, while fat tissue did not change. In obese mice the same chemical chaperone normalized blood sugar and cleared fatty liver [3,4].
• Eyes — in mice with inherited retinal degeneration, TUDCA preserved the photoreceptor layer and the electrical response of the retina; it did nothing in the fastest-degenerating strains. This is why it turns up in retinitis pigmentosa research [6].

References

1. Vang S, Longley K, Steer CJ, et al. The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases. Glob Adv Health Med. 2014;3(3):58-69. PMID 24891994. doi:10.7453/gahmj.2014.017
2. Rodrigues CM, Steer CJ. The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent. Expert Opin Investig Drugs. 2001;10(7):1243-53. PMID 11772248. doi:10.1517/13543784.10.7.1243
3. Kars M, Yang L, Gregor MF, et al. Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010;59(8):1899-905. PMID 20522594. doi:10.2337/db10-0308
4. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science. 2006;313(5790):1137-40. PMID 16931765. doi:10.1126/science.1128294
5. Ma H, Zeng M, Han Y, et al. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine (Baltimore). 2016;95(47):e5391. PMID 27893675. doi:10.1097/MD.0000000000005391
6. Drack AV, Dumitrescu AV, Bhattarai S, et al. TUDCA slows retinal degeneration in two different mouse models of retinitis pigmentosa and prevents obesity in Bardet-Biedl syndrome type 1 mice. Invest Ophthalmol Vis Sci. 2012;53(1):100-6. PMID 22110077. doi:10.1167/iovs.11-8544
7. Elia AE, Lalli S, Monsurrò MR, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016;23(1):45-52. PMID 25664595. doi:10.1111/ene.12664
8. Shefner JM, Cudkowicz ME. Failures to Replicate: What Recent Negative Phase 3 Trials Have Taught Us about Amyotrophic Lateral Sclerosis Clinical Research. Ann Neurol. 2024;96(2):211-215. PMID 38888068. doi:10.1002/ana.26999
9. TUDCA-ALS Consortium. Top-line results of the TUDCA-ALS phase 3 trial (press release, 27 March 2024), archived by the MND Association. https://www.mndassociation.org/sites/default/files/2024-10/27.03.24-TUDCA-TOPLINE-RESULTS_0.pdf